Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma
Open Access
- 4 November 2008
- Vol. 113 (11), 3242-3247
- https://doi.org/10.1002/cncr.23929
Abstract
BACKGROUND. Anapalsia is rare in childhood rhabdomyosarcoma and has not been included in the International Classification of Rhabdomyosarcoma (ICR). A recent review of cases from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG) suggests that anaplasia might be more common than previously reported and may impact clinical outcome. METHODS. The prevalence of anaplasia (focal or diffuse) was prospectively assessed in 546 eligible cases who were registered in an Intergroup Rhabdomyosarcoma Study Group (IRSG) or COG therapeutic trial from 1995 through 1998. The incidence of anaplasia in tumor samples and its impact in predicting clinical outcome was assessed. RESULTS. Overall, 71 (13%) of all samples analyzed had anaplasia. Anaplasia was more common in patients with tumors in favorable sites and was less commonly observed in younger patients and in those with stage II, III, or clinical group III disease. Regardless of its distribution (focal or diffuse), on univariate analysis the presence of anaplasia negatively influenced the failure‐free survival rate (63% vs 77% at 5 years) and overall survival (68% vs 82% at 5 years) rates in patients with embryonal rhabdomyosarcoma. This effect was most pronounced in children with intermediate‐risk tumors. Anaplasia did not affect outcome in patients with alveolar tumors. CONCLUSIONS. The incidence of anaplasia in patients with rhabdomyosarcoma is higher than previously described and may be of prognostic significance in children with intermediate‐risk embryonal rhabdomyosarcoma. Cancer 2008. © 2008 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- Defective Chromosome Segregation and Telomere Dysfunction in Aggressive Wilms' TumorsClinical Cancer Research, 2007
- Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology GroupJournal of Clinical Oncology, 2007
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: aberrations of 17p mapped to 17p13.2 by fluorescence in situ hybridizationLaboratory Investigation, 2004
- Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for MedulloblastomaJournal of Clinical Oncology, 2004
- Histopathologic grading of medulloblastomasCancer, 2002
- Focal Versus Diffuse Anaplasia in Wilms Tumor—New Definitions with Prognostic SignificanceThe American Journal of Surgical Pathology, 1996
- Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutationsNature Genetics, 1994
- Childhood Rhabdomyosarocoma with Anaplastic (Pleomorphic) FeaturesThe American Journal of Surgical Pathology, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958